Join
Live feed
·
PRReleasevia Quantisnow
Terns Pharmaceuticals Inc. logo

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

ByQuantisnow·Wall Street's wire, on your screen.
TERN· Terns Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TERN (Terns Pharmaceuticals Inc.) and more on Quantisnow.